ERBB2 and breast cancer: The ongoing Astefania trial (NCT04873362) is randomizing patients to receive standard T-DM1 therapy, with or without atezolizumab, for patients with high-risk, HER2+ breast cancer and residual disease after neoadjuvant therapy.